Stocks Overview

LAST PRICE
2.9100
TODAY'S CHANGE (%)
Trending Up0.0100 (0.3448%)

Bid / Lots
2.9100/ 2
Ask / Lots
3.0000/ 2
Open / Previous Close
2.8800 / 2.9000
Day Range
Low 2.6700
High 2.9100
52 Week Range
Low 0.1700
High 9.7700
Volume
447,258
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Friday's close: 2.9
Time	Volume	TPST
09:32 ET	5115	2.86
09:34 ET	9853	2.855
09:36 ET	1517	2.853
09:39 ET	193	2.86
09:41 ET	4972	2.87
09:43 ET	1946	2.88
09:45 ET	300	2.88
09:48 ET	6220	2.8507
09:52 ET	450	2.864
09:57 ET	1000	2.88
09:59 ET	700	2.86
10:03 ET	997	2.88
10:06 ET	429	2.86
10:08 ET	1075	2.86
10:12 ET	8220	2.85
10:14 ET	2000	2.84
10:17 ET	7519	2.81
10:19 ET	512	2.81
10:21 ET	24978	2.78
10:24 ET	865	2.789
10:26 ET	16063	2.76
10:28 ET	9343	2.74
10:30 ET	32742	2.7
10:32 ET	4692	2.7
10:33 ET	5239	2.7426
10:35 ET	2028	2.7349
10:37 ET	3550	2.755
10:39 ET	2380	2.745
10:42 ET	400	2.74
10:44 ET	100	2.75
10:48 ET	4825	2.75
10:51 ET	100	2.7485
10:53 ET	2000	2.7464
10:55 ET	500	2.75
11:00 ET	330	2.7499
11:02 ET	200	2.77
11:04 ET	11399	2.77
11:06 ET	100	2.77
11:08 ET	875	2.7501
11:09 ET	6134	2.74
11:11 ET	150	2.735
11:13 ET	1600	2.73
11:15 ET	2837	2.74
11:18 ET	100	2.74
11:20 ET	5578	2.77
11:22 ET	100	2.7688
11:24 ET	180	2.7699
11:26 ET	404	2.77
11:27 ET	500	2.7699
11:29 ET	1560	2.75
11:31 ET	2170	2.7386
11:33 ET	1130	2.732
11:36 ET	527	2.7399
11:38 ET	2940	2.755
11:40 ET	10100	2.76
11:49 ET	733	2.76
11:51 ET	19222	2.76
11:54 ET	100	2.77
11:56 ET	2000	2.76
11:58 ET	2950	2.78
12:00 ET	400	2.77
12:02 ET	2100	2.78
12:03 ET	100	2.78
12:05 ET	300	2.78
12:07 ET	200	2.775
12:09 ET	300	2.78
12:12 ET	250	2.79
12:14 ET	100	2.79
12:18 ET	2648	2.79
12:20 ET	6000	2.83
12:21 ET	12499	2.84
12:23 ET	630	2.8236
12:25 ET	1600	2.84
12:27 ET	100	2.86
12:30 ET	500	2.86
12:32 ET	200	2.85
12:34 ET	8937	2.8499
12:36 ET	2122	2.8599
12:39 ET	4041	2.8599
12:45 ET	13188	2.88
12:48 ET	370	2.89
12:50 ET	930	2.88
12:52 ET	1000	2.8701
12:54 ET	100	2.88
12:56 ET	2208	2.88
12:57 ET	358	2.8899
12:59 ET	1396	2.87
01:01 ET	100	2.87
01:03 ET	100	2.88
01:08 ET	100	2.88
01:10 ET	200	2.88
01:12 ET	1191	2.88
01:14 ET	710	2.878
01:19 ET	10023	2.861
01:21 ET	7172	2.85
01:24 ET	100	2.85
01:26 ET	1295	2.83
01:32 ET	225	2.8274
01:33 ET	1100	2.8479
01:35 ET	100	2.85
01:37 ET	100	2.85
01:44 ET	100	2.85
01:50 ET	400	2.8272
01:53 ET	100	2.8499
01:55 ET	1100	2.845
01:57 ET	800	2.85
02:00 ET	600	2.85
02:02 ET	1000	2.85
02:08 ET	600	2.85
02:18 ET	21100	2.88
02:20 ET	300	2.8799
02:22 ET	1100	2.8503
02:27 ET	100	2.86
02:38 ET	1900	2.85
02:40 ET	5487	2.85
02:45 ET	300	2.86
02:47 ET	1200	2.85
02:54 ET	4000	2.85
02:58 ET	6621	2.8504
03:00 ET	300	2.87
03:05 ET	100	2.87
03:09 ET	200	2.87
03:14 ET	500	2.87
03:16 ET	5930	2.88
03:18 ET	650	2.88
03:23 ET	100	2.88
03:27 ET	1100	2.88
03:30 ET	1900	2.88
03:32 ET	1000	2.88
03:34 ET	711	2.889
03:36 ET	4960	2.87
03:38 ET	555	2.88
03:41 ET	600	2.88
03:43 ET	5479	2.88
03:45 ET	2537	2.88
03:48 ET	100	2.89
03:50 ET	300	2.89
03:52 ET	499	2.8701
03:54 ET	12408	2.89
03:56 ET	440	2.8999
03:57 ET	2190	2.89
03:59 ET	2825	2.91

Data delayed at least 15 minutes.

Jun 7, 2024
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:30AM ET on Friday Jun 07, 2024 by Dow Jones
  4:30AM ET on Friday Jun 07, 2024 by Dow Jones
May 31, 2024
- Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST), from 3:45PM ET on Friday May 31, 2024 by Dow Jones
  3:45PM ET on Friday May 31, 2024 by Dow Jones
May 21, 2024
- Tempest to Participate in Upcoming Investor Conferences, from 8:00AM ET on Tuesday May 21, 2024 by Dow Jones
  8:00AM ET on Tuesday May 21, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesTPST Tempest Therapeutics Inc	64.4M	-1.7x	---
United StatesAVRO AVROBIO Inc	64.2M	2.1x	---
United StatesPASG Passage Bio Inc	64.7M	-0.7x	---
United StatesANTX AN2 Therapeutics Inc	64.7M	-0.8x	---
United StatesRLYB Rallybio Corp	64.0M	-0.8x	---
United StatesNVNO enVVeno Medical Corp	63.6M	-2.9x	---
As of 2024-06-17

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Contact Information

Headquarters: 2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
Phone: 415-798-8589
Fax: 302-655-5049

Executives

Independent Chairman of the Board: Michael Raab
President, Chief Executive Officer, Director: Stephen Brady
Executive Vice President, Chief Medical Officer: Samuel Whiting
Vice President - Strategy and Finance, Corporate Secretary: Nicholas Maestas
Independent Director: Geoffrey Nichol

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$64.4M
Revenue (TTM)	$0.00
Shares Outstanding	22.2M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	-1.67
EPS	$-1.76
Book Value	$1.21
P/E Ratio	-1.7x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Tempest Therapeutics Inc
NASDAQ:TPSTUnited States

Search Criteria

Charts

Recent News

Jun 7, 2024

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:30AM ET on Friday Jun 07, 2024 by Dow Jones

May 31, 2024

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST), from 3:45PM ET on Friday May 31, 2024 by Dow Jones

May 21, 2024

Tempest to Participate in Upcoming Investor Conferences, from 8:00AM ET on Tuesday May 21, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar